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Abstract The aim of this study was to determine whether luteal 
cells possess functional receptors for lysophosphatidic acid 
(LPA). We present evidence that |3H]LPA binds to a 38^t0 
kDa protein in a membrane fraction prepared from luteal cells 
and that this phospholipid is able to induce tyrosine phospho-
rylation of several proteins (65-125 kDa). Furthermore, LPA 
upregulates forskolin- and LH/GTP-stimulated adenylyl cyclase 
activity by changing its Vmax. Although a pertussis toxin-
sensitive G-protein has been reported to transmit the inhibitory 
signals between the LPA receptor and adenylyl cyclase, the 
observed upregulation of the enzyme activity in luteal cells is not 
abolished after pre-treating the cells with the toxin, suggesting 
that a different mechanism is operative in these cells. According 
to the pharmacological regulatory pattern it is suggested that the 
modulated adenylyl cyclase isoform is the enzyme subtype V 
expressed in luteal cells. 
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1. Introduction 
Lysophosphatidic acid (LPA) is a biologically active phos-
pholipid produced upon activation of secretory phospholipase 
A2 and hydrolysis of pre-existing phospholipids during plate-
let activation [1]. Though only freshly prepared platelet-rich 
plasma contains high amounts of LPA (2-20 μΜ), its produc-
tion and release is not restricted just to platelets [1-3]. LPA 
may also be formed and released by several types of injured 
cells [3] and it is present both in ascites from ovarian cancer 
cells [4] and in human follicular fluid [1]. 
This phospholipid is responsible for a variety of reported 
serum effects and has the potential to modulate cellular signal-
ling in various cell types determining their shape and differ-
entiation status [2,3]. Since LPA does not penetrate cells, it 
could either be metabolised in the cell membrane or bring 
about its effects upon binding to a receptor. Its biological 
activity has not yet been shown to be attributed to one of 
its metabolites. However a G-protein-coupled seven trans-
membrane receptor, identified by photoaffmity labelling and 
by molecular cloning, has been proposed as a candidate cell 
surface receptor for LPA [2,3,5-7]. 
Upon binding to its receptor, LPA has been shown to acti-
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vate several Ser/Thr kinases [8] and to cause rapid tyrosine 
phosphorylation of 110-130, 95 and 65-75 k D a proteins [8-
10]. Functionally LPA is known to induce at least four 
G-protein-mediated signal transduction cascades such as the 
stimulation of phospholipases С and D, inhibition of adenylyl 
cyclase and activation of ras [2,3]. Recent studies show that 
exposure of cells to LPA results in a modulat ion of their 
abilities to respond to hormones that interact with G-pro-
tein-linked receptors [11,12]. In the ovary, both steroid pro-
duction and the state of cellular differentiation are regulated 
primarily by the gonadotropin receptor-coupled adenylyl cy-
clase. Modulat ion of this enzyme may, therefore, have a ma-
jor consequence for the regulation of various differentiated 
cell functions in this system. We have reported previously 
[13] that treatment of bovine luteal cells with bacterial phos-
pholipase D can lead to an enhancement of forskolin- and 
LH-stimulated adenylyl cyclase activity. Since bacterial phos-
pholipase D has been shown to trigger its effects through 
activation of the LPA receptor [3], it was of interest to deter-
mine whether functional binding sites for LPA are present in 
luteal cells. Furthermore, possible biological responses to LPA 
in this cell system have also been evaluated. 
2. Materials and methods 
2.1. Materials 
The sources of chemicals were as follows: 1-oleoyl-LPA from Sig-
ma (Deisenhofen, Germany), [3H]oleoyl-LPA from NEN (Köln, Ger-
many), PTX from List Biological Laboratories Ine (Campbell, CA), 
TLC plates from Whatman (Maidstone, England), TLC solvents from 
Merck (Darmstadt, Germany), cyclic AMP assay reagents were pro-
vided by IBL Immunochemicals (Hamburg, Germany), peroxidase-
based Western blot detection systems from Pierce (provided from 
KMF Sankt Augustin, Germany) and alkaline phosphatase detection 
system Tropix from Serva (Heidelberg, Germany). Bovine LH was a 
gift from NIADDK (Bethesda, MD). Anti-phosphotyrosine antibody 
was from Upstate Biotechnology (Biomol, Hamburg, Germany), anti-
adenylyl cyclase antibodies were either a gift from Dr. Droste (Insti-
tute for Physiological Chemistry II, Heinrich-Heine University, Düs-
seldorf, Germany) or were obtained from Santa Cruz Biotechnology 
(Heidelberg, Germany). Secondary antibodies were from Dianova 
(Hamburg, Germany). All other reagents were obtained commercially 
and were of the highest purity grade. 
2.2. Cell culture and incubation 
The method for the isolation and purification of bovine luteal cells 
has been published elsewhere [13,14]. The cells were maintained in 
DMEM/HAM's F-12 Medium (incl. 2 mM glutamine, 100 U/ml pen-
icillin, 100 μg/ml streptomycin and 10% heat-inactivated foetal calf 
serum). On the second day, the medium was replaced by fresh me-
dium supplemented with 5 μg/ml bovine serum albumin, 5 μg/ml 
transferrin, 5 \i^)m\ insulin, 5 ng/ml sodium selenite and the cells 
were cultured further for 72 h before treatment. On day 5, culture 
medium was removed from the confluent cell monolayers and the cells 
were incubated with or without LPA in serum-free medium containing 
0.1% BSA. Unless otherwise stated, the cells were treated with 50 μΜ 
LPA for 15 min. The aspirated conditioned medium was used for 
further analysis, and the cell pellet was stored frozen for further treat-
ments (i.e. the membrane preparation). 
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2.3. Treatment of luteal membranes with LPA in vitro 
Preparation of luteal membrane fractions was performed as de-
scribed [13]. Their protein content was determined according to Brad-
ford [ 15]. The 100 000 X g membrane fractions were incubated in 100 μΐ 
with PIPES buffer, pH 7.0 in the presence of 10 mM MgCl2, 50 μΜ 
CaCl2, 50 μΜ EGTA, 100 μΜ ATP and various concentrations of 
oleic LPA. The samples were immediately centrifuged at 40000Xg at 
4°C for 60 min. The resulting pellet was used in adenylyl cyclase 
enzyme assay. 
2.4. Adenylyl cyclase assay 
The enzyme assay was carried out at 30°C for 15 min in a previ-
ously described [13] standard assay incubation mixture (100 μΐ) in-
cluding an ATP regenerating system, 1 mM ATP (or various ATP 
concentrations for kinetic analysis), 5 mM MgCl2 and 10 μg mem-
brane protein equivalent as indicated. After ethanol extraction, the 
amounts of cyclic AMP formed were measured either by radioimmu-
noassay as described previously [13,14] or by a specific cAMP-ELISA 
(IHF GmbH, Hamburg). The same anti-cAMP antibody [13,14] was 
used for either radioimmunoassay or ELISA. Enzyme kinetics were 
analysed according to the Lineweaver-Burk method. 
2.5. Analysis of [3H]LPA binding 
Membrane fractions were incubated with [3H]LPA in the presence 
and absence of cold LPA and 0.5 mM CuS04 with 20 mM Tris, pH 
7.5. The mixture (100 μΐ) was incubated for 60 min at 30°C after 
which 0.5 μΜ disuccinimidyl suberimate (DSS) was added to cross-
link LPA to its binding protein, and the membranes were incubated 
20 min at 4°C. Before heating in Laemmli sample buffer solubilising 
buffer was added (20 mM Tris pH 7.5, 1% SDS, 1 mM) and the 
samples were subjected to SDS-PAGE analysis. LPA cross-linked to 
its receptor protein was visualised with a help of a Berthold linear 
analyser system. The peak fractions were cut out of the gel, and the 
amounts of the bound radioactivity were counted in a beta counter. 
2.6. Assessment of [3H]LPA metabolism 
The membrane fractions were incubated with [3H]LPA in assay 
buffer (see binding) with and without CuS04 for 30 min at 30°C. 
The radioactive lipids were extracted from the membranes by the 
method of Bligh and Deyer [16] as described elsewhere [13]. The 
organic phases were dried, redissolved in 50 μΐ of CHCI3/CH3OH 
(9:1) and applied to silica gel G 60 linear high performance thin layer 
plates (HPTLC). The plates were developed using two different sol-
vent systems : first system consisting of chloroform/methanol/glacial 
acetic acid/water 75:48:12.5:3.5 [16] and the second one consisting 
of chloroform/methanol/acetic acid 65:15:2 [17,18] permitting the sep-
aration of LPA from phosphatidic acid, phospholipids and neutral 
lipids. Lipids were located by staining the standards with iodine va-
pour and autoradiography. The silica gel areas of interest were 
scraped and the amounts of the radioactivity extracted from these 
areas were measured in a scintillation counter. 
2.7. Analysis of phosphotyrosine phosphorylation 
The membrane fractions separated by SDS-PAGE and transferred 
onto PVDF membrane were blocked overnight followed by the incu-
bation with polyclonal anti-phosphotyrosine antibody overnight. The 
membrane was washed and incubated with peroxidase conjugated 
anti-rabbit secondary antibody for 60 min. The immunocomplex 
was detected using a peroxidase-based chemiluminescence detection 
system. No staining could be observed when rabbit non-immune se-
rum was applied as control. 
2.8. Expression of adenylyl cyclase Vprotein in bovine luteal cells 
Membranes were separated by SDS-PAGE, blocked and incubated 
with either polyclonal rabbit antibody recognising the peptide se-
quence corresponding to the 5' end of the coding region of the ad-
enylyl cyclase type V [19] or a polyclonal antibody mapping the amino 
acids 1019-1051 of the carboxy terminus of rat adenylyl cyclase V 
according to the protocol described above. The immunocomplex was 
detected using a peroxidase-based chemiluminescence detection sys-
tem. In some experiments alkaline-phosphatase conjugated monoclo-
nal antibody recognising all adenylyl cyclase isoforms (BBC2.AP) was 
used. The immunoreactive bands were visualised with Tropix-CDP-
Star solution. To avoid tissue-dependent non-specific reaction the 
membranes from rat heart were used as a positive control. 
2.9. Data presentation and analysis 
The statistical analyses (ANOVA and i-test) were carried out using 
GraphPAD Intuitive Software for Science (San Diego, CA). If not 
otherwise stated, the results are presented as mean ± SE (triplicate 
determinations) in a single representative experiment. Error bars 
have been omitted where these were smaller than the symbols. Each 
experiment was performed at least three times. 
3. Results 
3.1. [3H]LPA binds specifically to luteal membrane fraction 
Based on radioligand receptor cross-linking experiment, we 
show here that [3H]LPA is able to bind to a 38^10 k D a pro-
tein in luteal cell membranes (Fig. 1). Addit ion of unlabelled 
LPA could displace the binding of the radioligand in a con-
centration-dependent manner (Fig. 1). 
In order to determine to what extent the radioligand could 
be enzymatically degraded by lysophospholipases or acyl-
transferases in bovine luteal cells, we incubated the membrane 
fraction with [3H]LPA for 60 min after which lipids were 
extracted and separated by H P T L C (Fig. 2). The amounts 
of radioactivity associated with phosphatidic acid (PA) and 
lysophosphatidic acid were determined. After 60 min of incu-
bation, 26-28% of the radioactivity was associated with LPA, 
< 9 % was converted to PA, 45-50% to monoacylglycerol 
(MAG) and 10-14% to free fatty acid. 
3.2. LPA stimulates tyrosine phosphorylation of luteal 
membrane proteins 
Addition of LPA has been reported to cause tyrosine phos-
phorylation of multiple substrates in Swiss 3T3 cells and in rat 
fibroblasts [9,11,20,29]. To elucidate the functionality of LPA 
binding in luteal cells, it was of interest to see whether LPA is 
able to induce protein tyrosine phosphorylation in these cells. 
As shown in Fig. 3, addition of 1 μ Μ L P A is sufficient to 
stimulate phosphorylation of several membrane proteins. The 
most dramatic increase of phosphorylation on tyrosine resi-
dues is observed in the k D a range from 65-125. 
3.3. LPA sensitises both LH- and forskolin-stimulated adenylyl 
cyclase activity in vitro 
To test whether LPA treatment could directly affect luteal 
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Fig. 1. [3H]LPA binding to a 38 kDa membrane protein in bovine 
luteal cells. Membrane fractions were incubated with [3H]LPA and 
indicated amounts of cold LPA for 60 min at 30°C, after which the 
cross-linking of the radioligand receptor complex with disuccinimid-
yl suberimate and electrophoretic separation of membrane proteins 
were performed. The gel was scanned (A) and the amounts of the 
radioactivity in peak fractions were measured in a beta-counter (B). 
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Fig. 2. Assessment of [3H]LPA metabolism. Membrane fractions 
were incubated with [3H]LPA (0.5 nM) for 60 min (see Fig. 1). The 
radioactive membrane lipids were extracted and separated on 
HPTLC plates (see Section 2). Lane 1 (run in duplicate) shows the 
methanol/water fraction and lane 2 (duplicate) the chloroform frac-
tion. 
adenylyl cyclase activity, membrane fractions from LPA-
treated and untreated control cells were prepared and the 
enzyme activity was measured. As shown in Fig. 4, pre-treat-
ment of luteal cells with LPA resulted in a marked enhance-
ment of LH/GTP-stimulated adenylyl cyclase activity. This 
enhancing effect of LPA was dose-dependent; half maximal 
stimulation occurred with 800 nM LPA and a maximum effect 
was observed with 150-200 μΜ, diminishing thereafter with 
higher concentration of LPA (Fig. 4A). Kinetic analysis re-
vealed that the observed sensitisation of the enzyme activity 
resulted from a change in Vmax (7.28 versus 4.48 pmol/mg 
protein/min for LPA-treated versus untreated cells) with no 
effect on the Km of the enzyme (0.26 and 0.28 for treated and 
untreated cells respectively). 
Instead of intact cells, if membrane fractions were first pre-
pared and then treated with LPA an even more pronounced 
effect on both LH- and forskolin-stimulated adenylyl cyclase 
activity could be observed (Fig. 4B). Interestingly in this case, 
the stimulatory effect of LPA was dose-dependent and, unlike 
the cells, no inhibitory effect was observed even with as high a 
concentration of LPA as 400 μΜ (solubility limited the use of 
higher LPA concentrations). 
3.4. Pertussis toxin does not affect LPA-induced sensitisation 
of adenylyl cyclase 
LPA has been reported to cause both inhibition [21] and 
sensitisation [22] of adenylyl cyclase activity, and either of 
these effects could be completely abolished following PTX 
pre-treatment. Therefore, we have examined if this is the 
case for luteal cells as well. As shown in Fig. 5, treatment 
of the cells with LPA alone increased the rate of LH/GTP-
stimulated adenylyl cyclase reaction. Prior exposure of the 
cells to pertussis toxin caused a small augmentation of the 
enzyme activity. The sensitising effect of LPA in luteal cells 
was not blocked by pertussis toxin. On the contrary, an aug-
mentation was observed. This might be due to a different type 
of adenylyl cyclase in luteal cells compared to those used in 
other reported studies. 
Fig. 3. LPA-induced protein tyrosine phosphorylation in luteal cells. 
Membrane fractions were prepared from luteal cells treated with or 
without different LPA concentrations (1-1000 μΜ). The samples 
were run on SDS-PAGE, blotted onto PVDF membrane and hy-
bridised with specific anti-phosphotyrosine antibody. 
3.5. Bovine luteal cells express type V adenylyl cyclase 
Since there is absolutely no information in the literature as 
to which adenylyl cyclase isoform is present in the ovary, we 
demonstrate in the following set of experiments that adenylyl 
cyclase type V is present in luteal membranes. Based on West-
ern blotting procedure, we used at the outset a monoclonal 
antibody recognising several cyclase isoforms (Fig. 6, lanes 1 
and 2), then a polyclonal antiserum [19] recognising the pep-
tide sequence corresponding to 5' end of the coding region of 
the adenylyl cyclase type V (lanes 3 and 4) and finally poly-
clonal antibody raised against the carboxy terminus of rat 
adenylyl cyclase type V corresponding to amino acids 1019 
1051 (lanes 5 and 6). As a control (lane 7), membranes from 
rat heart, known to express type V adenylyl cyclase [19,24] 
were used. The results in Fig. 6 show that luteal cells appear 
to express a 150 kDa protein recognised by a non-selective 
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Fig. 4. Effects of pre-incubation of luteal cells (A) or membranes 
(B) with LPA on LH receptor-coupled adenylyl cyclase activity. 
A: Luteal cells were treated with various LPA concentrations for 
15 min and the membrane fractions were used in adenylyl cyclase 
assay performed in the presence of 100 ng/ml bovine LH and 10 μΜ 
GTP. B: Membrane fractions were incubated as described in Sec-
tion 2 with either various LPA concentrations or with 100 μΜ LPA 
(inset). The samples were centrifuged at 40000Xg and the resulting 
pellet was used in adenylyl cyclase assay performed in the presence 
of either buffer (no fill in), GTP (diagonal), LH/GTP ( · and hori-
zontal) or forskolin (solid). 
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anti-adenylyl cyclase antibody as well as by two different anti-
adenylyl cyclase type V-specific antibodies indicating that lu-
teal cells express this adenylyl cyclase isoform. 
4. Discussion 
The data presented here demonstrate that [3H]LPA binds to 
a 38^10 kD protein in luteal cell membranes and that this 
binding results in tyrosine phosphorylation of several mem-
brane proteins in the molecular weight range of 65-125 kDa. 
The lipid analysis of the cell fractions labelled with [3H]LPA 
shows clearly that it is metabolised to a variety of products. 
Of these, conversion to [3H]PA can be considered of only 
minor importance, suggesting that the observed LPA effects 
can not be explained by its conversion to phosphatidic acid. 
We observed further that pre-treatment of luteal cells or mem-
branes with LPA in vitro upregulates forskolin- as well as LH/ 
GTP-stimulated adenylyl cyclase activity as reflected in a 
change of the Vmax of the enzyme. Although a PTX-sensitive 
G-protein has been proposed to participate in transmitting the 
inhibitory/stimulatory signals between LPA receptor and ad-
enylyl cyclase, in luteal cells the observed LPA-induced upreg-
ulation of the enzyme activity was not abolished after PTX 
treatment, suggesting a different mode of action for these 
cells. The results from immunoblot analysis provided the evi-
dence that type V adenylyl cyclase is present in luteal cells. 
We have previously shown that phospholipase D is able to 
upregulate adenylyl cyclase in bovine luteal cells [13]. Consist-
ent with the reported finding [3] that phospholipase D treat-
ment of the cells activates putative endogenous LPA receptors 
we show here that [3H]LPA could be cross-linked to a mem-
brane protein of 38-40 kDa. Cold LPA displaced this binding 
in a dose-dependent manner indicating the specificity of the 
binding. A similar binding protein of about 40 kDa has been 
identified by photoaffmity labelling in various cell lines and in 
rat brain [5]. Although no LPA receptor has been purified so 
far, biochemical and molecular cloning data indicate the ex-
istence of multiple receptors for LPA-like mediators [6,25-28] 
widespread in different human tissues including the ovary [7]. 
In order to show functionality of LPA receptor in luteal 
cells, we took advantage of its ability to promote tyrosine 
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Fig. 5. Effects of PTX on LPA-induced sensitisation of adenylyl cy-
clase. The cells were treated for 180 min without (O, D) and with 
( · , ■) 10 ng/ml PTX and stimulated for further 15 min in the ab-
sence (o, · ) and presence (D, ■) of 100 μΜ LPA. The membrane 
fractions were used in the adenylyl cyclase assay performed in the 
presence of 100 ng/ml bovine LH and 10 μΜ GTP. 
Fig. 6. Detection of adenylyl cyclase type V in bovine luteal cells by 
Western blotting. Luteal membranes were run on SDS-PAGE, blot-
ted on to PVDF membrane and hybridised with different anti-ad-
enylyl cyclase (AC) antisera. Lanes 1, 2 show blots hybridised with 
antibody against common AC (lane 1 cytosol, lane 2 membrane). 
Lanes 3, 4 show membrane (lane 4) and cytosolic (lane 3) fractions 
analysed with the antibody-recognising peptide sequence of the cod-
ing region of AC V. Lanes 5, 6 (membrane and cytosol respectively) 
and lane 7 (rat heart control) show blots immunoanalysed with anti-
body recognising the carboxy terminus of rat AC V. 
phosphorylation in different cell systems in order to show 
that LPA induces tyrosine phosphorylation of a series of 
membrane bound proteins of 65-125 kDa in luteal cells. In 
other cell systems, LPA has been shown to phosphorylate 
proteins 110-130, 95, 65-75 and 42 kDa on tyrosine residues 
[29]. A non-receptor tyrosine kinase lying upstream of Rho 
has been suggested to transmit this LPA-elicited signals 
[2,3,30]. We show further that LPA sensitises the adenylyl 
cyclase in luteal cells by enhancing the Vmax of the enzyme. 
This agrees well with results published by Kreps et al. [11] and 
others [22], but is in contrast to reports where LPA has been 
shown to inhibit the cyclic AMP response [2,31]. Thus LPA 
has been reported to produce both stimulatory and inhibitory 
effects on forskolin- and hormone-stimulated adenylyl cyclase 
activity in diverse cells. Whether these effects of LPA are 
sensitive to PTX pre-treatment or not remains controversial. 
Unlike the Gi-mediated mitogenic response, the antimitogenic 
effect of LPA is not sensitive to PTX and is linked to an 
increase of cyclic AMP accumulation rather than decrease 
[32]. In 1321N1 cells and in human airway smooth muscle 
cells, however, LPA induces sensitisation of forskolin-stimu-
lated cyclic AMP accumulation by a PTX-sensitive mecha-
nism [11,12]. Interestingly however in the later report, PTX 
was unable to block the enhancement of isoproterenol-stimu-
lated adenylyl cyclase by LPA [12]. Thus, the mechanism in-
volved remains unclear. 
In previous studies, presence of a PTX-mediated ADP-ri-
bosylated protein has been reported [14] in bovine luteal cells 
[14]. Herrlich et al. [33] have identified two different PTX 
substrates in this cell system: Gi2 and Gi3, whereby only 
Gi2, but not Gi3 couples to LH receptor. PTX treatment 
augments LH-stimulated adenylyl cyclase activity in this cell 
system and partially abolished hCG-induced inositol forma-
tion [14,33]. However, we show here that the pre-treatment of 
bovine luteal cells with PTX did not abolish the LPA effects 
on the adenylyl cyclase activity, but even appeared to poten-
tiate further the upregulation of the cyclase. Thus although 
some data show impaired function of the inhibitory Gi-func-
tion in LPA-stimulated cell systems, these possibilities are 
obviously not mutually exclusive for the LPA actions. In bo-
vine luteal cells, the LH receptor has been shown [33] to 
couple simultaneously to both Gi2 and Gs, whereby as stim-
ulates adenylyl cyclase and βγ~ subunits from both Gi and Gs 
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stimulate phospholipase С ß2. In addition, dissociated a i сап 
cause an inhibition of the cyclase thus damping the stimula-
tory a s action [33,34] indicating that the observed augmenta-
tion of LH-coupled adenylyl cyclase in PTX-treated cells re-
sults from the withdrawal of the Gia-mediated inhibition. 
Since LPA and PTX have additive effects in this cell system, 
we propose that the mechanism of LPA's action as far as 
adenylyl cyclase augmentat ion is concerned is distinct in these 
cells and independent of Gi2 coupling. It is not possible to 
exclude that LPA may couple to Gi3 in these cells thus reg-
ulating other pathways. 
Cross-talk between adenylyl cyclase and other signalling 
cascades may occur via activation or inhibition of adenylyl 
cyclase by βγ~, a i subunits or by calcium released by another 
hormone not acting via Gs [35,36]. Although all mammalian 
cyclase isoforms are activated by Gsa , they differ dramatically 
in their response to other regulatory molecules with only a few 
common features [23,37]. Based on pharmacological charac-
teristics, such as stimulation with G s a , inhibition with G i a 
[33], additive effects of forskolin and GTP-analogs and pos-
itive modulat ion with protein kinase С [14], we can suggest 
that the adenylyl cyclase isoform being sensitised by LPA in 
luteal cells is presumably adenylyl cyclase type V. In fact we 
show that a protein band of 150 k D a is recognised by specific 
antibodies directed against adenylyl cyclase type V. These 
results certainly have to be confirmed on the molecular basis. 
In conclusion, one can assume that the different extent and 
nature of the LPA-induced modulat ion of the cyclase activity 
depend upon specific subtypes of adenylyl cyclase and G-pro-
tein couplings present in a particular cell. It is possible that 
cells expressing the same cyclase isoforms may be differentially 
modulated through different G-protein couplings. Alterna-
tively, expression of a given adenylyl cyclase isoform in a 
particular system may determine which regulatory pathway 
might be involved in the LPA regulation. 
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